Dr. William Ferguson treats children with cancer and blood disorders. His areas of expertise include hematopoietic stem cell transplantation, umbilical cord blood banking, use of genomic profiling for personalized cancer treatment, and new drug development for childhood cancer and sickle cell anemia. He participates in pediatric clinical trials for cancer, bone marrow transplantation, and sickle cell disease. Dr. Ferguson is a professor in the Department of Pediatrics, Division of Hematology-Oncology, at Saint Louis University School of Medicine, and director of the Division of Hematology-Oncology at SSM Health Cardinal Glennon Children's Hospital. Professional memberships include: American Society of Clinical Oncology; American Academy of Pediatrics; American Society of Hematology; American Society of Pediatric Hematology-Oncology; and Medical Advisory Board of the Bone Marrow Foundation. He is also a member of the Executive and Scientific Committees of the Beat Childhood Cancer Consortium. Dr. Ferguson sits on the editorial board of the Journal of Pediatrics.

Dr. Ferguson is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, Medulloblastoma, and Bone Marrow Aspiration.

Dr. Ferguson is board certified in American Board Of Pediatrics , Missouri Dept Of Health/Narcotics&Dangerous Drugs , Missouri State Board Of Registration, Drug Enforcement Administration , and American Board Of Pediatrics/Hematology-Oncology . He is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 59 clinical trials. Dr. Ferguson is currently accepting new patients.

Graduate Year

1982

Specialties

Palliative Medicine

Pediatrics

Oncology

Licenses

Pediatric Hematology-Oncology in MO

Board Certifications

American Board Of Pediatrics

Missouri Dept Of Health/Narcotics&Dangerous Drugs

Missouri State Board Of Registration

Drug Enforcement Administration

American Board Of Pediatrics/Hematology-Oncology

Fellowships

Massachusetts General Hospital

Hospital Affiliations

SSM Health Cardinal Glennon Children's Hospital

SSM Health Saint Louis University Hospital

Parkland Health Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem BCBS

Blue Cross Blue Shield

Cigna

Dean Health

Health Alliance

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Humana

HMO
INDEMNITY
POS
PPO

Managed Health Services

EPO
MANAGED MEDICAID PLAN
OTHER COMMERCIAL

Medicaid

OTHER MEDICAID
STATE MEDICAID

Meridian Choice

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D

Oscar

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 9 Less Insurance Carriers -

Locations

The Costas Center at SSM Health Cardinal Glennon Children's Hospital
1465 S. Grand Blvd., St. Louis, MO 63104

Call: 314-268-4000

Additional Areas of Focus

Dr. Ferguson has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Sickle Cell Disease

Hodgkin Lymphoma

Neuroblastoma

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

59 Clinical Trials

A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Newly Diagnosed High-Risk Neuroblastoma

Enrollment Status: Recruiting

Publish Date: September 04, 2026

Intervention Type: Drug

Study Drugs: Ceritinib, Dasatinib, Sorafenib, Vorinostat, DFMO

Study Phase: Phase 2

NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)